Shelf-Life Evaluation of Bilayered Human Skin Equivalent, MyDerm™
Open Access
- 23 August 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (8), e40978
- https://doi.org/10.1371/journal.pone.0040978
Abstract
Skin plays an important role in defense against infection and other harmful biological agents. Due to its fragile structure, skin can be easily damaged by heat, chemicals, traumatic injuries and diseases. An autologous bilayered human skin equivalent, MyDerm™, was engineered to provide a living skin substitute to treat critical skin loss. However, one of the disadvantages of living skin substitute is its short shelf-life, hence limiting its distribution worldwide. The aim of this study was to evaluate the shelf-life of MyDerm™ through assessment of cell morphology, cell viability, population doubling time and functional gene expression levels before transplantation. Skin samples were digested with 0.6% Collagenase Type I followed by epithelial cells dissociation with TrypLE Select. Dermal fibroblasts and keratinocytes were culture-expanded to obtain sufficient cells for MyDerm™ construction. MyDerm™ was constructed with plasma-fibrin as temporary biomaterial and evaluated at 0, 24, 48 and 72 hours after storage at 4°C for its shelf-life determination. The morphology of skin cells derived from MyDerm™ remained unchanged across storage times. Cells harvested from MyDerm™ after storage appeared in good viability (90.5%±2.7% to 94.9%±1.6%) and had short population doubling time (58.4±8.7 to 76.9±19 hours). The modest drop in cell viability and increased in population doubling time at longer storage duration did not demonstrate a significant difference. Gene expression for CK10, CK14 and COL III were also comparable between different storage times. In conclusion, MyDerm™ can be stored in basal medium at 4°C for at least 72 hours before transplantation without compromising its functionality.This publication has 29 references indexed in Scilit:
- Phase I/II Clinical Evaluation of StrataGraft: A Consistent, Pathogen-Free Human Skin SubstituteThe Journal of Trauma and Acute Care Surgery, 2009
- Apligraf in the Treatment of Neuropathic Diabetic Foot UlcersThe International Journal of Lower Extremity Wounds, 2009
- Keratinocyte–Fibroblast Interactions in Wound HealingJournal of Investigative Dermatology, 2007
- Treatment of partial‐thickness burns: a prospective, randomized trial using TranscyteTMAnz Journal of Surgery, 2004
- Skin substitutes: a reviewBurns, 2001
- Clinical Evaluation of an Acellular Allograft Dermal Matrix in Full-Thickness BurnsJournal of Burn Care & Rehabilitation, 1996
- Cornification and Basement Membrane Formation in a Bilayered Human Skin Equivalent Maintained at an Air-Liquid InterfaceJournal of Burn Care & Rehabilitation, 1992
- Stratified cornified primary cultures of human keratinocytes grown on microporous membranes at the air-liquid interfaceJournal of Dermatological Science, 1990
- Cell-cell interactions promote mammary epithelial cell differentiation.The Journal of cell biology, 1985
- A new composite skin prosthesisClinical Dermatology and Surgery, 1980